Intercept Pharmaceuticals Inc (ICPT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|44||2015||Independent Chairman of the Board|
|50||2002||President, Chief Executive Officer, Director|
|48||2016||Chief Financial Officer, Treasurer|
|50||2017||Chief Operating Officer|
- BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 Mln-$185 Mln
- BRIEF-Intercept Pharmaceuticals CEO Mark Pruzanski's FY 2017 Total Compensation Was $6.2 Million
- BRIEF-Intercept Pharmaceuticals Says Co's Board Increased Size Of Board From Nine Directors To Ten Directors
- BRIEF-Intercept Pharmaceuticals Announces Pricing Of Upsized $250 Mln Public Offering And Concurrent Private Placement Of Common Stock
- BRIEF-Intercept Sees Ocaliva Net Sales To Fall In Quarter Ended March 31